

Material Information (3176 MEDIGEN)

SEQ_NO	1	Date of announcement	2026/07/06	Time of announcement	14:52:22
Subject	Announcement of Important Resolution by all Directors of the Company's Important Subsidiary, MVA				
Date of events	2026/07/06	To which item it meets	paragraph 10		

Statement

- 1.Date of occurrence of the event:2026/07/06
- 2.Counterparty to the contract or commitment:Adara Bio Pty Ltd
- 3.Relationship with the Company:Subsidiary
- 4.Starting and ending dates (or rescission date) of the contract or commitment: Contract Signing Date
- 5.Major content (not applicable where rescinded):
All Directors of the Company's important subsidiary, Medic Vision AI Limited ("MVA"), resolved today (2026/07/06) to enter into a Subscription Agreement and a Shareholders Deed with Adara Bio Pty Ltd. Key points are as follows:
(1)Adara Bio Pty Ltd is a newly established joint venture between MVA and the Centre for Eye Research Australia Limited (CERA).
(2)Adara Bio Pty Ltd will develop CRISPR enabled RNA base pair editing therapies for the treatment of ocular genetic conditions.
(3)MVA will make its investment in two tranches. Upon Adara Bio Pty Ltd's achievement of specified milestones and MVA's payment of the second tranche of the investment, MVA will acquire a 50% equity ownership in Adara Bio Pty Ltd.
- 6.Restrictive covenants (not applicable where rescinded):none
- 7.Commitment (not applicable where rescinded):none
- 8.Any other important agreement (not applicable where rescinded):none
- 9.Effect on company finances and business:
There has been no material impact on the subsidiary's financial position or business operations.
- 10.Concrete purpose/objective:
To acquire gene therapy technologies and thereby strengthen the subsidiary's strategic positioning in the ophthalmic pharmaceutical field.
- 11.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 8 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
(1)The development of new drugs takes a long time, involves high investment costs and there is no guarantee of success. This may expose investment to risks and investors should exercise due diligence and invest with caution.